Artificial intelligence is rapidly becoming part of everyday Medical Affairs operations. From literature monitoring and insight generation to evidence planning, scientific communication, and stakeholder engagement, AI tools are changing how teams access, interpret, and apply information. However, the organisations achieving the greatest value from AI are not necessarily those with the most advanced platforms or the largest technology investments. The difference often comes down to whether teams have developed the confidence and capability to use these tools effectively.

Two Medical Affairs teams within the same organisation can have access to identical technology, budgets, and governance frameworks, yet experience completely different outcomes. One team may integrate AI into weekly workflows, using it to accelerate scientific review and uncover insights, while another may continue relying entirely on traditional processes. The difference is rarely the availability of technology alone; it is the mindset, curiosity, and willingness of people to experiment, learn, and adapt.

Digital confidence has therefore become a new Medical Affairs capability. It represents the ability to understand what AI can support, critically evaluate its outputs, and apply it responsibly within scientific workflows. The future of AI adoption in Medical Affairs will depend less on replacing human expertise and more on creating teams that can combine scientific judgement with machine intelligence.

The Current State of AI Readiness in Medical Affairs

Although AI adoption is accelerating across the pharmaceutical industry, readiness remains inconsistent. Many Medical Affairs teams recognise the potential of AI but remain uncertain about where to begin, how to assess outputs, and how to integrate these tools into established scientific processes.

Current challenges include variable understanding of AI capabilities and limitations, uncertainty around evaluating AI-generated information, concerns about bias and transparency, and limited integration of digital analytics into evidence strategy. In addition, training opportunities are often inconsistent across teams and regions, creating different levels of confidence among professionals.

Early adopters are already demonstrating the practical value of AI across multiple Medical Affairs activities. AI-assisted literature monitoring can help teams identify relevant publications faster, insight summarisation tools can transform large volumes of field feedback into structured themes, and digital analytics can reveal patterns in stakeholder engagement. However, the value comes when these tools are incorporated into workflows with appropriate scientific review and governance.

AI adoption can be viewed as a maturity spectrum. At one end, some teams remain in the “ignoring” stage, where AI is viewed mainly as a risk or temporary trend. Others are “experimenting,” with individual professionals testing tools informally for specific tasks. More advanced teams are “applying” AI routinely for defined workflows such as literature triage, first-draft summaries, or insight organisation with human validation. The most mature organisations reach the “integrating” stage, where AI-supported processes become part of standard operating models and contribute directly to evidence generation and engagement strategies.

The important observation is that adoption does not always correlate with company size, resources, or technical capability. A large organisation with extensive AI infrastructure may struggle if teams lack ownership and confidence. Meanwhile, a smaller team may achieve significant progress because one motivated professional champions experimentation and creates momentum. Ultimately, people determine whether technology becomes a capability or simply another unused platform.

The Roadmap to Building Digital Confidence

Phase 1 (2025–2026): Awareness and Foundations

The first step toward AI-enabled Medical Affairs is building shared understanding. Teams need clarity on what AI can and cannot reliably support, particularly within scientific and regulated environments.

Foundational education should focus on core AI concepts, responsible use, data quality, bias awareness, and the importance of human oversight. Medical Affairs professionals do not need to become data scientists, but they need enough understanding to question outputs, recognise limitations, and make informed decisions.

A practical starting point is identifying one low-risk, repetitive task where AI can be tested alongside existing workflows. For example, a team may compare traditional manual review of congress abstracts with an AI-assisted approach, assessing where the technology improves efficiency and where expert interpretation remains essential. The objective is not simply to prove that AI is better, but to build practical judgement about when and how it adds value.

Phase 2 (2027–2028): Practical Application in Daily Workflows

Once teams develop foundational confidence, the focus shifts toward embedding AI into everyday Medical Affairs activities. This includes using AI-supported insight synthesis for advisory boards, congress intelligence, field medical feedback, and scientific content development.

One of the most important emerging skills is the ability to effectively communicate with AI systems. High-quality outputs depend heavily on the quality of instructions provided. For example, a basic request such as “summarise this publication” may generate a broad overview, whereas a scientifically focused request asking for the study population, endpoints, limitations, safety findings, and supporting evidence sections produces a far more useful and reviewable output.

Structured training and workflow support, such as those provided through platforms and services developed by organisations including MphaR, can help Medical Affairs teams translate AI capabilities into practical, compliant, and scientifically meaningful applications.

During this phase, teams also need clear review processes. AI should accelerate scientific work, but every output requires appropriate expert validation before being incorporated into decision-making or external communication.

Phase 3 (2029–2030): Strategic Integration into Evidence and Engagement Planning

The final stage is where AI becomes embedded within the strategic thinking of Medical Affairs. Rather than being used only for operational efficiency, AI becomes a tool for anticipating scientific needs and guiding evidence strategies.

Integrated teams will use AI-generated insights to identify evidence gaps, understand evolving stakeholder priorities, optimise engagement approaches, and support lifecycle planning. Digital signals, real-world data, and scientific intelligence can be combined to create a more dynamic understanding of therapeutic landscapes.

However, sustainable adoption requires repeatable processes rather than dependence on individual champions. Organisations should document AI-supported workflows, define governance pathways, and establish clear ownership. This transforms individual experimentation into an organisational capability.

Enablers of AI Upskilling in Medical Affairs

Successful AI adoption requires alignment across people, processes, technology, and culture. People remain the most important enabler. The future Medical Affairs workforce will include professionals who combine scientific expertise with digital confidence. MSLs, Medical Directors, medical writers, insight analysts, and digital specialists will increasingly work together to interpret AI-generated intelligence and convert it into meaningful scientific action.

Processes are equally important. Teams need structured approaches for AI output review, bias assessment, governance, and documentation. Without defined workflows, AI adoption may become inconsistent or create compliance concerns.

Technology provides the foundation, including AI summarisation tools, scientific intelligence platforms, digital engagement systems, and analytics dashboards. However, technology should support clearly defined needs rather than drive adoption alone. Purchasing a platform without understanding the workflow it is intended to improve often results in limited utilisation.

Compliance-ready digital ecosystems, including platforms used by MphaR, support responsible AI adoption by enabling structured scientific engagement, traceable workflows, and transparent management of information. Additionally, culture ultimately determines success. Teams that encourage curiosity, experimentation, and responsible questioning are more likely to benefit from AI. A digitally confident culture does not mean accepting every AI output; it means having the confidence to evaluate, challenge, and improve it.

For Medical Affairs leaders, the priority is investing in capability development rather than only technology acquisition. Building AI literacy, governance frameworks, and cross-functional collaboration will determine long-term success.

Measuring Digital Confidence and AI Readiness

Measuring AI maturity requires looking beyond simple tool adoption. Having access to an AI platform does not necessarily indicate successful implementation. More meaningful indicators include the ability of teams to critically evaluate AI outputs, the quality and consistency of AI-supported insights, improvements in evidence planning speed, integration of analytics into strategic decisions, and confidence among Medical Affairs professionals.

Organisations should also assess whether AI-supported workflows maintain scientific quality, compliance standards, and traceability. The goal is not simply faster output generation, but better decision-making. A useful approach is regularly assessing where teams sit on the adoption spectrum: ignoring, experimenting, applying, or integrating. The key question is not “How many people have access to AI tools?” but rather “What behaviour would move the team one step further toward effective adoption?” Continuous feedback, benchmarking, and shared learning help transform isolated successes into scalable organisational capability.

Conclusion: From AI Awareness to AI-Enabled Medical Leadership

The future of Medical Affairs will not be defined by artificial intelligence replacing scientific expertise. It will be defined by teams that understand how to combine human judgement with machine intelligence. AI can accelerate information processing, reveal hidden patterns, and support more informed decisions, but the interpretation of scientific meaning remains a human responsibility. The organisations that succeed will be those that develop digital confidence across their teams-professionals who are curious enough to explore AI, critical enough to challenge outputs, and scientifically grounded enough to apply insights responsibly.

The difference between AI leaders and AI observers will not simply be access to technology. It will be the willingness of individuals and teams to begin building new ways of working. As Medical Affairs moves toward a more data-driven and insight-led future, organisations that invest in people, capability building, and responsible AI adoption will be positioned to transform AI from a technological opportunity into a strategic advantage.